Novartis and Albumedix have entered into an agreement to evaluate the development of several first-in-class therapeutics using Albumedix’s Veltis technology platform and associated technologies.   Novartis will evaluate molecules in combination with Albumedix´s engineered albumin variants for enhanced delivery. Beyond the modulation of pharmacokinetic profiles, the potential for novel routes of administration and mechanisms of action will be assessed. Novartis will evaluate Albumedix’s Veltis ...